title: In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparations.
abstract: OBJECTIVE
  To compare in vitro and in vivo biological and biochemical properties of five liquid intravenous immunoglobulin (IVIg) preparations licensed for therapeutic use in Europe.
  
  
  METHODS
  ClairYg(®) was compared in a blinded manner to four other liquid IVIg preparations licensed in Europe (Octagam(®) , Kiovig(®) , Gamunex(®) , Privigen(®) ). Three batches of each preparation were tested, except for the IgG repertoires and the animal model.
  
  
  RESULTS
  Levels of anti-A and anti-B antibodies were lower in ClairYg(®) (0·11/0·11) relative to a positive EDQM standard and Octagam(®) (0·11/0·08) than in other preparations (0·33-0·69/0·42-0·46). IgG in ClairYg(®) recognized 365 and 416 protein spots in HEp-2 cell and Escherichia coli protein extracts vs. 230-330 and 402-842 protein spots, respectively, for IgG in other preparations. IgA content (301 vs. 165-820 ng/mg of IgG), Factor XI and Factor XII antigen (0·46 vs. 0·85-2·40 mU/mg of IgG and 7·8 vs. 20·0-46·2 lU/mg of IgG) C1q binding (0·42 vs. 0·67-1·89 arbitrary units) and C5a uptake (0·41 vs. 0·45-0·66% of activation) were lower in ClairYg(®) than in other preparations. Finally, intravenous infusion of ClairYg(®) , Gamunex(®) and Privigen(®) had no major effect on arterial blood pressure in spontaneously hypertensive rats.
  
  
  CONCLUSIONS
  Our results evidence some differences in the biological and biochemical properties among licensed liquid IVIg preparations.
authors.affiliation: LFB Biotechnologies, Courtaboeuf, France Université Paris Descartes, Faculté de Médecine, Institut Cochin, INSERM U1016, Paris, France.
authors.forename: F
authors.initials: F
authors.lastname: Dhainaut
authors.forename: P-O
authors.initials: PO
authors.lastname: Guillaumat
authors.forename: H
authors.initials: H
authors.lastname: Dib
authors.forename: G
authors.initials: G
authors.lastname: Perret
authors.forename: A
authors.initials: A
authors.lastname: Sauger
authors.forename: C
authors.initials: C
authors.lastname: de Coupade
authors.forename: M
authors.initials: M
authors.lastname: Beaudet
authors.forename: M
authors.initials: M
authors.lastname: Elzaabi
authors.forename: L
authors.initials: L
authors.lastname: Mouthon
mesh_terms: D000818:Animals; D062186:Arterial Pressure / Q000187:drug effects; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage* / Q000737:chemistry* / Q000276:immunology; D008297:Male; D051381:Rats
chemical_list: D016756:Immunoglobulins, Intravenous